Dehydration News and Research

Latest Dehydration News and Research

Spectrum signs definitive agreement to acquire Allos

Spectrum Pharmaceuticals and Allos Therapeutics, Inc. today announced that they have signed a definitive agreement under which Spectrum will acquire all of the outstanding shares of Allos for $1.82 per share in cash plus one Contingent Value Right.

6 Apr 2012

Anti-ceramide antibody may prevent radiation gastrointestinal syndrome

A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident.

5 Apr 2012

Combination treatment shows promise against NSCLC patients ineligible for bevacizumab

A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

4 Apr 2012

Eisai, University of Kansas grant water-soluble pro-drug technology patent to OneWorld Health

OneWorld Health (OWH), a nonprofit that develops lifesaving medicines for neglected diseases, announced that it has signed a nonexclusive patent agreement with Eisai Co., Ltd., for a water-soluble pro-drug technology patent. OWH will use the pro-drug technology to advance development of iOWH032, its new drug to treat acute secretory diarrhea.

2 Apr 2012

Factors that increase the possibility of having migraines

A migraine is the most common type of headache that propels patients to seek care from their doctors. Roughly 30 million Americans suffer from migraine headaches, with women affected almost three times more often than men, according to statistics from the National Headache Foundation in Chicago.

21 Mar 2012

FDA denies AstraZeneca Citizen Petitions on SEROQUEL labeling

AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.

12 Mar 2012

Mysterious kidney disease 'devastating' Central America's Pacific Coast, AP reports

The Associated Press/Seattle Times reports on a "mysterious epidemic that is devastating the Pacific Coast of Central America, killing more than 24,000 people in El Salvador and Nicaragua since 2000 and striking thousands of others with chronic kidney disease at rates unseen virtually anywhere else."

7 Mar 2012

MTPC, Medicago partner to develop and commercialize three new vaccines

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the establishment of a strategic alliance with Mitsubishi Tanabe Pharma Corporation (MTPC) through the execution of a Master Research Collaboration Agreement.

6 Mar 2012

Ten symptoms and signs that a child may need a doctor

Unfortunately, kids get sick. Fighting a virus or common cold is good for a child's immune system and can help build antibodies that protect them from dangerous illnesses. Still, there are times when that tummy ache or cough may require medical attention.

2 Mar 2012

State roundup: Calif. expands uninsured access, gives adult day care reprieve

Nearly two years before the federal health reform law kicks in, 10 California counties have expanded medical coverage to more than 250,000 people who were previously uninsured, according to new state data.

22 Feb 2012

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.

13 Feb 2012

New guidelines for travellers to avoid DVT on long flights

New guidelines for travellers have been issued. Experts warn that those with a higher risk of serious blood clots who opt for the window seat on flights longer than four hours are potentially putting themselves in danger. People who should be most concerned are those who have recently had surgery, cancer patients, those with limited mobility, the severely obese, and travellers over 70. However, healthy women on the pill and those who are pregnant should also be careful, according to the guidelines by the American College of Chest Physicians.

7 Feb 2012

New ACCP guidelines address DVT/PE risk factors for long-distance travel

New evidence-based guidelines from the American College of Chest Physicians (ACCP) address the many risk factors for developing a deep vein thrombosis (DVT), or blood clot, as the result of long-distance travel.

7 Feb 2012

Merck receives FDA approval for JANUMET XR to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration approved JANUMET XR (sitagliptin and metformin hydrochloride extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA (sitagliptin), with extended-release metformin.

3 Feb 2012

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

Novartis announced today that following a priority review, the US Food and Drug Administration has approved an update to the Gleevec (imatinib mesylate) tablets label to recommend 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the risk of recurrence inclusion criteria of the pivotal trial.

1 Feb 2012

Interim results from Allos Therapeutics' FOLOTYN and bexarotene Phase 1 combination study on CTCL

Allos Therapeutics, Inc. today reported interim results from the Company's ongoing Phase 1 combination study of FOLOTYN and bexarotene in patients with relapsed or refractory cutaneous T-cell lymphoma.

31 Jan 2012

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy.

30 Jan 2012

Family, friends encourage young people to use sunbeds

As the post-Christmas January blues take hold, young people are risking damage to their health and appearance by using sunbeds on the recommendation of friends and family, according to a new survey by Cancer Research UK.

20 Jan 2012

Low-voltage alternating current can effectively eradicate E. coli on beef

A short burst of low voltage alternating current can effectively eradicate E. coli bacteria growing on the surface of even heavily contaminated beef, according to a study published in the International Journal of Food Safety, Nutrition and Public Health. The technique offers an inexpensive and easy to implement approach to reducing the risk of food poisoning, which can occur despite handlers complying with hygiene standards.

12 Jan 2012

Expert offers tips to lose weight

It happens every year, millions of Americans make resolutions to lose weight. Most persons end that pledge after the first few weeks of the New Year but experts at My Weight Doctor® say it may be that people are trying too hard to make quick changes. The experts say that making small, gradual changes to boost your metabolism will lead to better habits.

4 Jan 2012